CD22 and acute lymphoblastic leukemia: Novel immune-targeted therapies (e.g., drugs targeting the B cell-associated antigens CD19 (blinatumomab) and CD22 (inotuzumab) provide a potential means of circumventing chemo-refractory B-ALL cells through novel mechanisms of action and of preventing minimal residual disease (MRD).